Business Summary

CHS Pharma Inc. (CHS) is a Biotechnology Development Company located in South Florida. CHS owns an Intellectual property portfolio for potential treatments related to Ischemic Stroke, Dry Macular Degeneration as well as other age related disorders such as Alzheimer’s disease. These technologies were developed by Dr. Jang-Yen Wu, Dr. Howard Prentice and their colleagues. Dr. Wu is a Senior Fellow and Distinguished Professor at Florida Atlantic University’s Charles E. Schmidt College of Medicine. Dr. Prentice is a Professor of Biomedical Science in the Charles E. Schmidt College of Medicine. Dr. Wu has published more than 300 papers in journals such as Science, Nature, PNAS, among others. He has made a great impact in biomedical sciences, particularly in basic and translational neuroscience, and is recognized as one of the most cited scientists in the world identified by Current Contents/ISI (2002). In translational neuroscience, Dr. Wu and his team have developed several mechanism-based treatments for neurodegenerative diseases including Parkinson’s disease, Ischemic Stroke, Alzheimer’s disease and Epilepsy. His inventions are quite novel and several patents have been awarded to him and his team. Dr. Prentice has over 70 publications in numerous journals including PNAS, EMBO Journal, Cell, Molecular Neurobiology, and Molecular and Cell Biology. Dr. Prentice’s principal research interests are in tissue hypoxia and ischemia and in molecular pathways of neuroprotection in stroke therapy.

Daniel Laskowitz M.D. will be guiding CHS in the commercialization process. Dr. Laskowitz is Professor and Vice Chair of Neurology at Duke University’s School of Medicine, one of the nation’s top medical schools. Dr. Laskowitz designed one of the first multicenter trials evaluating the role of serum biomarkers in stroke (the BRAIN study), and the first translational study evaluating the use of statins in subarachnoid hemorrhage. He has served as the site PI for a number of trials in stroke and acute brain injury, including SOCRATES, COBIS, SyNAPSe, and ACTION. He is a fellow of the American Heart Association, American Academy of Neurology, and the American Neurological Association, and has authored and co-authored more than 170 peer-reviewed articles. His research interests pertain to examining the role of microglial activation and endogenous CNS inflammatory response in exacerbating secondary injury following acute brain insult. 

The Problem

Traumatic brain injury (TBI) and stroke collectively are the third leading cause of death and the leading cause of disability in the United States. The National Institute of Health (NIH) stated that healthcare costs for the treatment of stroke exceed 73 billion dollars in the U.S. every year.

15 million Americans suffer from signs and symptoms of Dry Macular Degeneration (AMD), and an estimated 27 to 30 million are affected worldwide.

The Opportunity

We offer two unique opportunities: A multi-drug combination therapy  to reverse the effects of an Ischemic Stroke and an effective way to slow the progression of Dry Macular Degeneration. There are no effective medical solutions currently available on the market for either of these two medical conditions. 

Target Markets

The Ischemic Stroke/Traumatic Brain Injury market is expected to reach a market value of USD 1.9 billion by 2020, growing at a CAGR of 6.3%. There are 795,000 patients diagnosed with stroke in the U.S. every year, wherein 85% of the total cases were identified as acute ischemic stroke. 

According to the National Eye Institute, the global market to treat “dry” AMD is expected to be $2.1 billion with a CAGR of 10.3% starting in 2016. The “dry” AMD market has the  market potential of more than $5 billion, especially with the increase in population of the elderly that may result in a doubling of AMD cases by 2050. Since there is currently no known cure for “dry” AMD, blockbuster status would most likely be guaranteed for a drug that can tackle this disease. 



Competitive Advantages

For TBI/Stroke: The combination treatment at 10% of the normally prescribed dose decreased the damage to the brain by more than 40%. 

For Dry Macular Degeneration:The study results for a drug treatment for damage to RPE cells could be achieved in a cost effective, relatively nontoxic therapeutic approach for AMD (Publication of the National Academy of Science, 2014”Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α”).